![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NEUROLOGIX SIGNS STRATEGIC LICENSE AGREEMENT FOR COMPONENT OF ITS PARKINSON'S GENE THERAPY PRODUCT
NEUROLOGIX SIGNS STRATEGIC LICENSE AGREEMENT FOR COMPONENT OF ITS PARKINSON'S GENE THERAPY PRODUCT
August 7, 2006
Neurologix, Inc., a biotech company committed to developing innovative gene therapies for the brain and central nervous system, announced that it has entered into a licensing agreement with a subsidiary of Diamyd Medical, a biotechnology company based in Stockholm, Sweden, and Pittsburgh, PA.
Business
Wire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct